Catalysts · GSK · CIK 1131399 · page 3 of 4

GSK catalysts and FDA events, page 3.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on GSK PDUFA dates and upcoming catalysts. This page continues the list.

Upcoming catalysts (continued)

DateDrugCompanyEventIndicationStatusSource
July 2030Month disclosedmocertatug rezetecanGSKPrimary completionOvarian NeoplasmsScheduledClinicalTrials.gov
Aug to Nov 2030Quarter disclosedbelantamab mafodotinGSKTopline readoutMultiple MyelomaScheduledClinicalTrials.gov
August 2030Month disclosedbelantamab mafodotinGSKPrimary completionMultiple MyelomaScheduledClinicalTrials.gov
Sep to Dec 2030Quarter disclosedBenlysta (belimumab)GSKTopline readoutConnective Tissue DiseasesScheduledClinicalTrials.gov
Sep to Dec 2030Quarter discloseddepemokimab (GSK3511294)GSKTopline readoutAsthmaScheduledClinicalTrials.gov
September 2030Month discloseddepemokimab (GSK3511294)GSKPrimary completionAsthmaScheduledClinicalTrials.gov
September 2030Month disclosedBenlysta (belimumab)GSKPrimary completionConnective Tissue DiseasesScheduledClinicalTrials.gov
Oct 2030 to Jan 2031Quarter disclosedefimosfermin alfaGSKTopline readoutMetabolic Dysfunction-associated SteatohepatitisScheduledClinicalTrials.gov
October 2030Month disclosedefimosfermin alfaGSKPrimary completionMetabolic Dysfunction-associated SteatohepatitisScheduledClinicalTrials.gov
Nov 2030 to Feb 2031Quarter disclosedJemperli (dostarlimab)GSKTopline readoutEndometrial Carcinoma; Neoplasms, EndometrialScheduledClinicalTrials.gov
November 2030Month disclosedJemperli (dostarlimab)GSKPrimary completionEndometrial Carcinoma; Neoplasms, EndometrialScheduledClinicalTrials.gov

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
June 17, 2026Utebzi (tebipenem pivoxil hydrobromide)GSKFDA approval—ApprovedFDA Novel Drug Approvals
June 17, 2026GSK3036656GSKTopline readoutTuberculosisCompletedClinicalTrials.gov
Jun 2026Month disclosed—GSKFDA approvalcomplicated urinary tract infectionsApprovedSEC Form 8-K
May 27, 2026Vocabria (cabotegravir sodium)GSKPrimary completionHIV InfectionsCompletedClinicalTrials.gov
May 18, 2026Nucala (mepolizumab)GSKTopline readoutAsthmaCompletedClinicalTrials.gov
May 14, 2026GSK4527226GSKPrimary completionAlzheimer's DiseaseWithdrawnClinicalTrials.gov
May 14, 2026dtg/3tcGSKTopline readoutHIV; HIV InfectionsCompletedClinicalTrials.gov
May 11, 2026flu mrna (formulation a) (GSK6479720A)GSKPrimary completionInfluenza, HumanCompletedClinicalTrials.gov
May 4, 2026Nucala (mepolizumab)GSKTopline readoutHypereosinophilic SyndromeCompletedClinicalTrials.gov
April 15, 2026Tivicay (dolutegravir sodium)GSKPrimary completionHIV; HIV InfectionsCompletedClinicalTrials.gov
March 24, 2026linerixibat (GSK2330672)GSKPDUFA date—ScheduledSEC Form 8-K
March 9, 2026Wellcovorin (leucovorin calcium)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
Mar 2026Month disclosed—GSKPDUFA date—ScheduledSEC Form 8-K
January 31, 2026GSK4532990GSKPrimary completionNonalcoholic Fatty Liver Disease; Non-alcoholic Fatty Liver DiseaseCompletedClinicalTrials.gov
January 23, 2026dtg/3tcGSKPrimary completionHIV; HIV InfectionsCompletedClinicalTrials.gov
January 15, 2026gsk3511294 (depemokimab) (GSK3511294)GSKTopline readoutAsthmaCompletedClinicalTrials.gov
January 14, 2026zanamivirGSKPrimary completionInfluenza, Human; ArthralgiaCompletedClinicalTrials.gov
December 16, 2025Exdensur (depemokimab-ulaa)GSKComplete Response Letter—CRL issuedFDA Complete Response Letters
December 16, 2025Exdensur (depemokimab-ulaa)GSKFDA approval—ApprovedFDA Novel Drug Approvals
December 15, 2025rmenb+omv nz vaccineGSKPrimary completionMeningitisCompletedClinicalTrials.gov
December 11, 2025Blujepa (gepotidacin mesylate)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
December 11, 2025—GSKPDUFA date—ScheduledSEC Form 8-K
Dec 2025Month disclosedazithromycinGSKPDUFA date—ScheduledSEC Form 8-K
Dec 2025Month disclosed—GSKLabel expansionuncomplicated urogenital gonorrhoea in patients 12 years of age and olderApprovedSEC Form 8-K
November 11, 2025HIBSAGO (bepirovirsen)GSKPrimary completionChronic Hepatitis B; Hepatitis B, ChronicCompletedClinicalTrials.gov
November 3, 2025HIBSAGO (bepirovirsen)GSKPrimary completionChronic Hepatitis B; Hepatitis B, ChronicCompletedClinicalTrials.gov
October 28, 2025Nucala (mepolizumab)GSKPrimary completionHypereosinophilic SyndromeCompletedClinicalTrials.gov
October 27, 2025efimosfermin (BOS-580)GSKPrimary completionNonalcoholic Steatohepatitis (NASH)CompletedClinicalTrials.gov
October 23, 2025Blenrep (belantamab mafodotin-blmf)GSKComplete Response Letter—CRL issuedFDA Complete Response Letters
October 23, 2025Blenrep (belantamab mafodotin-blmf)GSKFDA approval—ApprovedopenFDA Drugs@FDA
October 23, 2025—GSKPDUFA date—ScheduledSEC Form 8-K
October 21, 2025altsonflex1-2-3 dose aGSKPrimary completionDiarrhoeaCompletedClinicalTrials.gov
October 1, 2025GSK3915393GSKPrimary completionIdiopathic Pulmonary FibrosisWithdrawnClinicalTrials.gov
September 23, 2025GSK4532990GSKPrimary completionNon-alcoholic Fatty Liver DiseaseCompletedClinicalTrials.gov
September 18, 2025AFX3772GSKPrimary completionPneumonia, Bacterial; Pneumococcal Infections; Pneumonia, PneumococcalCompletedClinicalTrials.gov
September 16, 2025dtg/3tcGSKPrimary completionHIV InfectionsCompletedClinicalTrials.gov
September 14, 2025Nucala (mepolizumab)GSKPrimary completionAsthmaCompletedClinicalTrials.gov
September 2, 2025salbutamol hfa-134aGSKPrimary completionAsthmaCompletedClinicalTrials.gov
August 5, 2025HIBSAGO (bepirovirsen)GSKPrimary completionHepatitis B, ChronicCompletedClinicalTrials.gov
July 30, 2025—GSKAdvisory committee—CompletedSEC Form 8-K
July 29, 2025GSK1070806GSKPrimary completionDermatitis, AtopicWithdrawnClinicalTrials.gov
July 23, 2025GSK1070806GSKPrimary completionDermatitis, AtopicWithdrawnClinicalTrials.gov
July 23, 2025—GSKPDUFA date—ScheduledSEC Form 8-K
July 17, 2025Blenrep (belantamab mafodotin-blmf)GSKAdvisory committee—NegativeFDA advisory committee calendar
June 20, 2025Benlysta (belimumab)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
June 18, 2025ZEJULA (niraparib)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
June 5, 2025cobolimab (GSK4069889)GSKPrimary completionLung Cancer, Non-Small CellCompletedClinicalTrials.gov
June 3, 2025rsvpref3 oa investigational vaccineGSKPrimary completionRespiratory Syncytial Virus InfectionsCompletedClinicalTrials.gov
May 27, 2025GSK3036656GSKPrimary completionTuberculosisCompletedClinicalTrials.gov
May 22, 2025Nucala (mepolizumab)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
May 19, 2025gsk3511294 (depemokimab) (GSK3511294)GSKPrimary completionAsthmaCompletedClinicalTrials.gov
March 25, 2025Blujepa (gepotidacin mesylate)GSKFDA approvalTo treat uncomplicated urinary tract infectionsApprovedFDA Novel Drug Approvals
Mar 2025Month disclosed—GSKFDA approvalfemale adultsApprovedSEC Form 8-K
February 14, 2025—GSKFDA approval—ApprovedSEC Form 8-K
February 14, 2025—GSKPDUFA date—ScheduledSEC Form 8-K
September 20, 2024Cabenuva Kit (cabotegravir; rilpivirine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
September 20, 2024Vocabria (cabotegravir sodium)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
August 1, 2024Jemperli (dostarlimab-gxly)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
May 16, 2024Benlysta (belimumab)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
April 5, 2024Dovato (dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
September 15, 2023OJJAARA (momelotinib)GSKFDA approvalTo treat intermediate or high-risk myelofibrosis in adults with anemiaApprovedFDA Novel Drug Approvals
Sep 2023Month disclosed—GSKPDUFA date—ScheduledSEC Form 8-K
July 31, 2023Jemperli (dostarlimab-gxly)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
June 15, 2023Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
April 26, 2023ZEJULA (niraparib)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
April 26, 2023ZEJULA (niraparib)GSKFDA approval—ApprovedopenFDA Drugs@FDA
March 1, 2023Arnuity Ellipta (fluticasone furoate)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
February 15, 2023Benlysta (belimumab)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
February 9, 2023Jemperli (dostarlimab-gxly)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
February 1, 2023Jesduvroq (daprodustat)GSKFDA approval—ApprovedFDA Novel Drug Approvals
January 25, 2023Dovato (dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
December 8, 2022ZEJULA (niraparib)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
November 30, 2022Brexafemme (ibrexafungerp)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
March 30, 2022Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
March 30, 2022Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine)GSKFDA approval—ApprovedopenFDA Drugs@FDA
March 23, 2022Cabenuva Kit (cabotegravir; rilpivirine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
March 23, 2022Vocabria (cabotegravir sodium)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
January 31, 2022Cabenuva Kit (cabotegravir; rilpivirine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
January 31, 2022Vocabria (cabotegravir sodium)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
January 24, 2022Rukobia (fostemsavir tromethamine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
January 20, 2022Dovato (dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
December 20, 2021Vocabria (cabotegravir sodium)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
December 20, 2021Vocabria (cabotegravir sodium)GSKFDA approval—ApprovedopenFDA Drugs@FDA
December 10, 2021Epzicom (abacavir sulfate; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
August 17, 2021Jemperli (dostarlimab-gxly)GSKFDA approval—ApprovedopenFDA Drugs@FDA
July 29, 2021Nucala (mepolizumab)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
July 9, 2021Juluca (dolutegravir sodium; rilpivirine hydrochloride)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
July 9, 2021Tivicay (dolutegravir sodium)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
June 1, 2021Brexafemme (ibrexafungerp)GSKFDA approval—ApprovedopenFDA Drugs@FDA
Every catalyst is quoted from GSK’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.